Contemporary Perspectives on the Role of Vitamin D in Enhancing Gut Health and Its Implications for Preventing and Managing Intestinal DiseasesReview Published on 2024-07-202024-09-05 Journal: Nutrients [Category] update2024, [키워드] gut microbiome IBD IBS Intestinal barrier Vitamin D [DOI] 10.3390/nu16142352 PMC 바로가기 [Article Type] Review
Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational StudyArticle Published on 2024-03-272024-09-05 Journal: Vaccines [Category] update2024, [키워드] biologics hepatitis B IBD infliximab ulcerative colitis [DOI] 10.3390/vaccines12040364 PMC 바로가기 [Article Type] Article
SARS-CoV-2 vaccination in inflammatory bowel disease patients is not associated with flares: a retrospective single-centre Swiss studyGastroenterology Published on 2024-01-302024-09-05 Journal: Annals of Medicine [Category] update2024, [키워드] Flares IBD SARS-CoV-2 vaccination [DOI] 10.1080/07853890.2023.2295979 PMC 바로가기 [Article Type] Gastroenterology
Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel DiseaseBrief Communications Published on 2023-09-222024-09-05 Journal: The American journal of gastroenterology [Category] update2024, [키워드] adverse events IBD SARS-CoV-2 serology [DOI] 10.14309/ajg.0000000000002337 PMC 바로가기 [Article Type] Brief Communications
Immunization of children with inflammatory bowel disease against SARS-CoV-19 infection: A prospective single centre cohort studyarticle Published on 2023-08-192024-09-05 Journal: Vaccine: X [Category] update2024, [키워드] children COVID-19 infection IBD immunization SARS-CoV2 immunization [DOI] 10.1016/j.jvacx.2023.100374 PMC 바로가기 [Article Type] article
Leukocytoclastic Vasculitis in a Patient With Crohn Disease: A Case ReportCase Report Published on 2023-06-262024-09-05 Journal: Journal of investigative medicine high impact case [Category] update2024, [키워드] Crohn disease Dermatology gastroenterology IBD Inflammatory bowel disease lcv Leukocytoclastic vasculitis PCSVV primary cutaneous small vessel vasculitis small vessel vasculitis [DOI] 10.1177/23247096231181865 PMC 바로가기 [Article Type] Case Report
COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desireArticle Published on 2023-04-012023-07-09 Journal: Gastroenterología y hepatología [Category] COVID19(2023년), [키워드] Additional vaccine dose Agentes biológicos biologic agents COVID-19 vaccination Dosis vacuna adicional EII IBD Vacunación COVID-19 [DOI] 10.1016/j.gastrohep.2022.05.009 PMC 바로가기
Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel DiseaseArticle Published on 2022-12-292023-07-11 Journal: Nutrients [Category] COVID19(2023년), [키워드] cholecalciferol COVID-19 Crohn’s disease IBD monoclonal antibodies SARS-CoV-2 ulcerative colitis Vitamin D [DOI] 10.3390/nu15010169 PMC 바로가기
COVID-19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposalArticle Published on 2022-12-012022-11-16 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] abdominal pain ACE2 acute respiratory syndrome addition association Autoimmune bowel Care caused coronavirus coronavirus disease COVID-19 COVID-19 epidemic diarrhea disease downregulated enzyme Epidemic etiology exacerbate expressed feasibility Genetic IBD IL-17 Imbalance immune activation immunosuppressive drug increase induce Infection Inflammatory Inflammatory bowel disease inflammatory disease Inflammatory response intestinal intestinal inflammation intestine lung mechanism nonspecific overlapping pathway Patient patients Pneumonia progression protective factor receptor Research respiratory inflammation risk risk of COVID-19 SARS-CoV-2 SARS-COV-2 infection Symptom systemic symptom the cytokine storm the SARS-CoV-2 Treatment upregulated vaccination [DOI] 10.1002/jmv.28067 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기